Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Fineline Cube Feb 24, 2026
Company Deals

Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform

Fineline Cube Feb 14, 2026
Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Fineline Cube Feb 14, 2026
Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Fineline Cube Feb 14, 2026
Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Fineline Cube Feb 14, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

Fineline Cube Feb 24, 2026
Company Drug

Sino Biopharma’s Benmelstobart Secures Fourth NMPA Approval for Stage III NSCLC – Expanding PD‑L1 Franchise in China

Fineline Cube Feb 14, 2026
Company Drug

Pfizer’s Talzenna (talazoparib) Approved by China’s NMPA for mCRPC Treatment

Fineline Cube Nov 7, 2024

The National Medical Products Administration (NMPA) website has indicated that Pfizer’s (NYSE: PFE) marketing filing...

Company Drug

Shouyao Holdings Adjusts Development Strategy for SY-1530, Halts Monotherapy Clinical Trials

Fineline Cube Nov 7, 2024

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its...

Company Drug

Nanjing Leads Biolabs Secures FDA Orphan Drug Designation for LBL-034 in Multiple Myeloma Treatment

Fineline Cube Nov 7, 2024

Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced that it has received...

Company Drug

Sanofi’s Dupixent Gains EMA Approval for Eosinophilic Esophagitis in Children

Fineline Cube Nov 7, 2024

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...

Company Deals

Novartis Forges Partnerships at CIIE to Strengthen Radioligand Therapy Ecosystem in China

Fineline Cube Nov 7, 2024

At the 7th China International Import Expo (CIIE), Swiss pharmaceutical giant Novartis (NYSE: NVS) announced...

Drug Medical Device Policy / Regulatory

China’s NHC Announces Initiative to Boost Gerontology Medical Services

Fineline Cube Nov 7, 2024

The National Health Commission (NHC) has issued a notification aimed at enhancing gerontology medical service...

Company Deals

Vantive Secures Collaborations with Kertone and Qiantang Longyue at CIIE for Dialysis Solutions

Fineline Cube Nov 7, 2024

Vantive, a planned spin-off from U.S.-based Baxter International (NYSE: BAX) specializing in kidney care, has...

Company Drug

Amgen’s Tavneos Receives NMPA Approval for ANCA-Associated Vasculitis Treatment in China

Fineline Cube Nov 7, 2024

US biotechnology company Amgen (NASDAQ: AMGN) has announced that it has received market approval in...

Company Medical Device

Boston Scientific Launches Vercisie Genius DBS System in China for Parkinson’s Disease Treatment

Fineline Cube Nov 7, 2024

US major Boston Scientific Corporation (NYSE: BSX) has officially launched its Vercisie Genius, an implantable...

Company Drug

CARSgen Therapeutics Presents Latest CAR-T Data at ASH Annual Meeting

Fineline Cube Nov 6, 2024

CARSgen Therapeutics Holdings Ltd (HKG: 2171), a China-based specialist in chimeric antigen receptor (CAR)-T cell...

Company Drug

Changchun High & New Technology Industries Receives NMPA Approval for Long-Acting Somatropin

Fineline Cube Nov 6, 2024

Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading China-based company, has...

Company Drug

Huadong Medicine Co., Ltd Receives NMPA Approval for Stelara Biosimilar SaiLeXin

Fineline Cube Nov 6, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...

Company Deals

Northeast Pharmaceutical to Acquire Majority Stake in Dingcheng Peptide Source for RMB 186.8 Million

Fineline Cube Nov 6, 2024

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced its intention to acquire a 70%...

Company Drug

Ascentage Pharma to Present Olverembatinib and Lisaftoclax Clinical Data at ASH Annual Meeting

Fineline Cube Nov 6, 2024

China-based Ascentage Pharma (HKG: 6855) has announced that it will present the results of multiple...

Company Drug

CStone Pharmaceuticals Presents CS5001 Clinical Data at the ASH Annual Meeting

Fineline Cube Nov 6, 2024

China-based CStone Pharmaceuticals (HKG: 2616) has announced the presentation of the latest clinical data on...

Company Drug

Roche to Showcase 40+ Abstracts on Blood Disorders at ASH Annual Meeting

Fineline Cube Nov 6, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has announced plans to present over 40 abstracts across...

Company Drug

China Medical System’s Opzelura Approved in Hong Kong for Non-segmental Vitiligo Treatment

Fineline Cube Nov 6, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that the market filing for its...

Company Drug

Legend Biotech to Showcase CARTITUDE-4 Trial Data on Carvykti at ASH Annual Meeting

Fineline Cube Nov 6, 2024

China-based Legend Biotech Corporation (NASDAQ: LEGN) is set to present new data on minimal residual...

Company Deals

Shanghai Duoning Biotechnology Partners with Branca Bunús for Transfection Reagents Innovation

Fineline Cube Nov 6, 2024

Shanghai Duoning Biotechnology Co., Ltd, a prominent biopharmaceutical company in China, has entered into a...

Policy / Regulatory

NMPA Draft Proposal Aims to Strengthen Supervision of Drug Entrusted Manufacturing

Fineline Cube Nov 6, 2024

The National Medical Products Administration (NMPA) has released a draft proposal titled “Announcement on Strengthening...

Posts pagination

1 … 231 232 233 … 625

Recent updates

  • Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China
  • Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit
  • FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies
  • Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel
  • Pfizer Partners with Sciwind Biosciences for Ecnoglutide China Rights – $495M Deal Marks Metabolic Market Entry
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China

Company Drug

Sichuan Biokin’s Iza‑Bren Hits PFS and OS Endpoints in Phase III TNBC Study – First Bispecific ADC to Show Dual Survival Benefit

Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Company Deals

Gilead Sciences to Acquire Arcellx for $7.8B – Bolsters CAR‑T Pipeline with BCMA‑Targeted Anito‑cel

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.